This has been called “curative” TACE by the recent Asian-Pacific consensus statement [10] in order to emphasize the difference as compared with TACE achieving a partial response in which, conversely, surviving hypoxic tumours frequently change to sarcomatous or mixed hepato-cholangiocellular phenotypes and induce vascular endothelial growth factor, which additionally promotes tumour progression [53–55]. The gene discussed is VEGFA; the disease is neoplasm.